EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mortality risk in patients with autosomal dominant polycystic kidney disease

Deirdre Mladsi, Xiaolei Zhou, Gregory Mader, Myrlene Sanon, Jinyi Wang, Christine Barnett, Cynthia Willey, Stephen Seliger

BMC Nephrology · 16.02.2024 · 25 (1)

DOI: 10.1186/s12882-024-03484-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BMC Nephrology, online erschienen am 16.02.2024. Verfasst von Deirdre Mladsi und 7 weiteren Autor:innen. Beteiligte Einrichtung: RTI Health Solutions, Research Triangle Park, NC, USA. dmladsi@rti.org. Hauptthemen laut MEDLINE: Polycystic Kidney, Autosomal Dominant, Kidney Failure, Chronic, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Otsuka Pharmaceutical Development and Commercialization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Autosomal dominant polycystic kidney disease (ADPKD) is the leading inheritable cause of end-stage renal disease (ESRD). Mortality data specific to patients with ADPKD is currently lacking; thus, the aim of this study was to estimate mortality in patients with ADPKD.

Methods

We analyzed data from the United States Renal Data System (USRDS) for patients with ADPKD available during the study period of 01/01/2014–12/31/2016, which included a cohort of patients with non-ESRD chronic kidney disease (CKD) and a cohort of patients with ESRD. Mortality rates with 95% confidence intervals (CIs) were calculated overall and by age group, sex, and race for the full dataset and for a subset of patients aged ≥ 65 years. Adjusted mortality hazard ratios (HRs) were calculated using Cox regression modeling by age group, sex, race, and CKD stage (i.e., non-ESRD CKD stages 1–5) or ESRD treatment (i.e., dialysis and transplant).

Results

A total of 1,936 patients with ADPKD and non-ESRD CKD and 37,461 patients with ADPKD and ESRD were included in the analysis. Age-adjusted mortality was 18.4 deaths per 1,000 patient-years in the non-ESRD CKD cohort and 37.4 deaths per 1,000 patient-years in the ESRD cohort. As expected, among the non-ESRD CKD cohort, patients in CKD stages 4 and 5 had a higher risk of death than patients in stage 3 (HR = 1.59 for stage 4 and HR = 2.71 for stage 5). Among the ESRD cohort, patients receiving dialysis were more likely to experience death than patients who received transplant (HR = 2.36). Age-adjusted mortality among patients aged ≥ 65 years in the non-ESRD CKD cohort was highest for Black patients (82.7 deaths per 1,000 patient-years), whereas age-adjusted mortality among patients aged ≥ 65 years in the ESRD cohort was highest for White patients (136.1 deaths per 1,000 patient-years).

Conclusions

Mortality rates specific to patients aged ≥ 65 years suggest racial differences in mortality among these patients in both non-ESRD CKD and ESRD cohorts. These data fill an important knowledge gap in mortality estimates for patients with ADPKD in the United States.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Kidney, Autosomal DominantKidney Failure, ChronicRenal Insufficiency, ChronicHumansUnited StatesRenal DialysisKidneyDisease Progression

Stichwörter der Autor:innen

Autosomal dominant polycystic kidney diseaseEnd-stage renal diseaseMortality

Autor:innen und Institutionen

  • RTI Health Solutions, Research Triangle Park, NC, USA. dmladsi@rti.org.
  • RTI Health Solutions, Research Triangle Park, NC, USA.
  • Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA.
  • University of Rhode Island, Kingston, RI, USA.
  • University of Maryland School of Medicine, Baltimore, MD, USA.

Förderung

  • Otsuka Pharmaceutical Development and Commercialization

Zitieren

APA

Mladsi, D., Zhou, X., Mader, G., Sanon, M., Wang, J., Barnett, C., Willey, C., & Seliger, S. (2024). Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrology, 25(1). https://doi.org/10.1186/s12882-024-03484-3

Vancouver

Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, et al. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrology. 2024;25(1). doi:10.1186/s12882-024-03484-3

BibTeX
@article{Mladsi2024,
  author = {Mladsi, Deirdre and Zhou, Xiaolei and Mader, Gregory and Sanon, Myrlene and Wang, Jinyi and Barnett, Christine and Willey, Cynthia and Seliger, Stephen},
  title = {Mortality risk in patients with autosomal dominant polycystic kidney disease},
  journal = {BMC Nephrology},
  year = {2024},
  volume = {25},
  number = {1},
  doi = {10.1186/s12882-024-03484-3}
}
Kostenlos starten →